152 related articles for article (PubMed ID: 10023504)
21. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Zohar J; Insel TR
Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
[TBL] [Abstract][Full Text] [Related]
22. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial.
Noorbala AA; Hosseini SH; Mohammadi MR; Akhondzadeh S
J Clin Pharm Ther; 1998 Apr; 23(2):155-9. PubMed ID: 9786103
[TBL] [Abstract][Full Text] [Related]
23. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA
J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614
[TBL] [Abstract][Full Text] [Related]
24. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
Dell'Osso B; Nestadt G; Allen A; Hollander E
J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
[TBL] [Abstract][Full Text] [Related]
25. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
[TBL] [Abstract][Full Text] [Related]
27. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
Zohar J; Judge R
Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
[TBL] [Abstract][Full Text] [Related]
28. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
[TBL] [Abstract][Full Text] [Related]
29. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR
Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220
[TBL] [Abstract][Full Text] [Related]
30. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
[TBL] [Abstract][Full Text] [Related]
31. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
Albert U; Aguglia E; Maina G; Bogetto F
J Clin Psychiatry; 2002 Nov; 63(11):1004-9. PubMed ID: 12444814
[TBL] [Abstract][Full Text] [Related]
32. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
[TBL] [Abstract][Full Text] [Related]
33. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
[TBL] [Abstract][Full Text] [Related]
34. New pharmacologic approaches to obsessive compulsive disorder.
Insel TR
J Clin Psychiatry; 1990 Oct; 51 Suppl():47-51; discussion 56-8. PubMed ID: 2120204
[TBL] [Abstract][Full Text] [Related]
35. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
Varigonda AL; Jakubovski E; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
[TBL] [Abstract][Full Text] [Related]
37. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
Marazziti D; Pfanner C; Palego L; Gemignani A; Milanfranchi A; Ravagli S; Lensi P; Presta S; Cassano GB
Pharmacopsychiatry; 1997 Nov; 30(6):245-9. PubMed ID: 9442546
[TBL] [Abstract][Full Text] [Related]
38. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Maina G; Albert U; Salvi V; Bogetto F
J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
[TBL] [Abstract][Full Text] [Related]
39. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.
Karameh WK; Khani M
Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26221004
[TBL] [Abstract][Full Text] [Related]
40. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
Pato MT; Hill JL; Murphy DL
Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]